Form 8-K - Current report:
SEC Accession No. 0000950170-24-095439
Filing Date
2024-08-12
Accepted
2024-08-12 16:12:28
Documents
14
Period of Report
2024-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20240812.htm   iXBRL 8-K 40051
2 EX-99.1 awh-ex99_1.htm EX-99.1 252237
3 GRAPHIC img245972787_0.jpg GRAPHIC 135062
4 GRAPHIC img245972787_1.jpg GRAPHIC 15115
  Complete submission text file 0000950170-24-095439.txt   630250

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT awh-20240812.xsd EX-101.SCH 25815
16 EXTRACTED XBRL INSTANCE DOCUMENT awh-20240812_htm.xml XML 4896
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 241196897
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)